title: Sensitivity and specificity of immunohistochemical markers used in the diagnosis of epithelioid mesothelioma: a detailed systematic analysis using published data.
abstract: OBJECTIVE
  Immunohistochemistry is frequently employed to aid the distinction between mesothelioma and pulmonary adenocarcinoma metastatic to the pleura, but there is uncertainty as to which antibodies are most useful. We analysed published data in order to establish sensitivity and specificity of antibodies used to distinguish between these tumours with a view to defining the most appropriate immunohistochemical panel to use when faced with this diagnostic problem.
  
  
  RESULTS
  A systematic analysis of the results of 88 published papers comparing immunohistochemical staining of a panel of antibodies in mesothelioma with epithelioid areas, and pulmonary adenocarcinoma metastatic to the pleura. Results for a total of 15 antibodies were analysed and expressed in terms of sensitivity and specificity. The most sensitive antibodies for identifying pulmonary adenocarcinoma were MOC-31 and BG8 (both 93%), whilst the most specific were monoclonal CEA (97%) and TTF-1 (100%). The most sensitive antibodies to identify epithelioid mesothelioma were CK5/6 (83%) and HBME-1 (85%). The most specific antibodies were CK5/6 (85%) and WT1 (96%).
  
  
  CONCLUSIONS
  No single antibody is able to differentiate reliably between these two tumours. The use of a small panel of antibodies with a high combined sensitivity and specificity is recommended.
authors.affiliation: South Manchester University Hospitals NHS Trust, Wythenshawe Hospital and Christie Hospital NHS Trust, Manchester, UK. julietk@talk21.com
authors.forename: J E
authors.initials: JE
authors.lastname: King
authors.forename: N
authors.initials: N
authors.lastname: Thatcher
authors.forename: C A C
authors.initials: CA
authors.lastname: Pickering
authors.forename: P S
authors.initials: PS
authors.lastname: Hasleton
mesh_terms: D000230:Adenocarcinoma / Q000737:chemistry / Q000175:diagnosis*; D000912:Antibodies, Neoplasm / Q000032:analysis; D000951:Antigens, Neoplasm / Q000032:analysis; D014408:Biomarkers, Tumor / Q000032:analysis*; D015820:Cadherins / Q000032:analysis; D064032:Calbindin 2; D002272:Carcinoembryonic Antigen / Q000032:analysis; D003937:Diagnosis, Differential; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods*; D016256:Lewis X Antigen; D008175:Lung Neoplasms / Q000737:chemistry / Q000175:diagnosis*; D008654:Mesothelioma / Q000737:chemistry / Q000175:diagnosis*; D010997:Pleural Neoplasms / Q000737:chemistry / Q000175:diagnosis*; D064030:S100 Calcium Binding Protein G / Q000032:analysis; D012680:Sensitivity and Specificity; D018180:Thrombomodulin / Q000032:analysis; D014746:Vimentin / Q000032:analysis
chemical_list: D000912:Antibodies, Neoplasm; D000951:Antigens, Neoplasm; C091202:B72.3 antibody; D014408:Biomarkers, Tumor; D015820:Cadherins; D064032:Calbindin 2; D002272:Carcinoembryonic Antigen; C407642:Leu-M1 antigen; D016256:Lewis X Antigen; D064030:S100 Calcium Binding Protein G; D018180:Thrombomodulin; D014746:Vimentin